Mergers & AcquisitionsMedium•16 November 2026•
1 min read
Johnson & Johnson to Acquire Ollin Biosciences for $3.3 Billion
Key Facts
1Johnson & Johnson agreed to pay $2.2 billion upfront to acquire biotech firm Ollin Biosciences.
2Blackstone Life Sciences will provide $750 million to fund Phase 3 development of the retinal disease treatment OLN324.
3The deal includes potential milestone payments of up to $1.125 billion.
Johnson & Johnson agreed to pay $2.2 billion upfront to acquire the biotechnology firm Ollin Biosciences. BioSpace reported that the deal includes potential milestone payments of up to $1.125 billion, bringing the total transaction value to approximately $3.3 billion. The acquisition is intended to bolster the company's retinal disease portfolio, specifically targeting the development of the OLN324 treatment.
Blackstone Life Sciences will provide $750 million to fund the Phase 3 development of the retinal disease treatment OLN324 as part of the agreement. Following the announcement, Johnson & Johnson (JNJ) closed at $285.75 on November 13, 2026, while Blackstone (BX) closed at $120.19 on the same date.